Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis

Nelli, Fabrizio; Natoli, Guido; Moscetti, Luca; Massari, Annalisa; D’Auria, G.; Fabbri, Agnese; Frittelli, Patrizia; Ruggeri, Enzo Maria

doi:10.1179/1973947812y.0000000059

Cited by 1 publication

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A treated with HT may have a better response rate (RR), PFS, and overall survival (OS) post-relapse [16,[24][25][26] and appear to be less sensitive to treatment with chemotherapy [27] than luminal subtype B tumors.…”

Section: Can Luminal a And B Mbc Subtypes Be Differentiated Using Immmentioning

confidence: 99%

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

et al. 2020

View full text Add to dashboard Cite

Purpose Hormone receptor (HR)-positive, Human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) requires a therapeutic approach that takes into account multiple factors, with treatment being based on antiestrogen hormone therapy (HT). As consensus documents are valuable tools that assist in the decision-making process for establishing clinical strategies and optimize the delivery of health services, this consensus document has been created with the aim of developing recommendations on cretiera for hormone sensitivity and resistance in HER2-negative luminal MBC and facilitating clinical decision-making. Methods This consensus document was generated using a modification of the RAND/UCLA methodology, which included the definition of the project and identification of issues of interest, a non-exhaustive systematic review of the literature, an analysis and synthesis of the scientific evidence, preparation of recommendations, and external evaluation with a panel of 64 medical oncologists specializing in breast cancer. Results A Spanish panel of experts reached consensus on 32 of the 32 recommendations/conclusions presented in the first round and were accepted with an approval rate of 100% about definition of metastatic disease not susceptible to local curative treatment, definition of hormone sensitivity and hormone resistance in metastatic luminal disease and therapeutic decision-making. Conclusion We have developed a consensus document with recommendations on the treatment of patients with HER2negative luminal MBC that will help to improve therapeutic benefits.

show abstract

Section: Can Luminal a And B Mbc Subtypes Be Differentiated Using Immmentioning

confidence: 99%

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

Epirubicin and docetaxel as first-line treatment for hormonal receptor positive metastatic breast cancer: the predictive value of luminal subtype: A retrospective cohort analysis

Abstract: Identification by Ki67 labelling index of human epidermal growth factor receptor-2-negative luminal A could predict a substantial benefit from systemic chemotherapy. Endocrine therapy would be the most appropriate therapy for luminal A tumours.

Cited by 1 publication

References 26 publications

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer

Contact Info

Product

Resources

About